NYSE · Medical Instruments & Supplies · USD
Teleflex Incorporated (TFX) Stock Analysis
Teleflex Incorporated (TFX) is a Medical Instruments & Supplies stock listed on NYSE and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
TFX Key Statistics
As of Sep 4, 2026Trading
- Open
- $138.70
- Previous Close
- $139.96
- Day's Range
- 137.35–140.59
- 52-Week Range
- 100.18–145.00
- Volume
- 464.50K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.81
Valuation
- Market Cap
- $5.86B
- P/E Ratio
- unprofitable
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 12.63
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- 0.16
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 2.60
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.53
Financials (FY)
- Revenue (FY)
- $1.99B+17.25%
- Net Income (FY)
- −$905.64M−1399.81%
- Profit marginThe share of revenue left as profit after all costs and taxes.
- −45.76%
- Shares Outstanding
- 42.37M
- 1-Year Return
- +8.11%
Dividend and dates
- Dividend
- $1.36+0.97%
- Ex-Dividend Date
- August 14, 2026
- Earnings Date
- October 29, 2026
- Avg Volume
- 525.94K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
TFX Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +14.00% |
| 2025 | −30.67% |
| 2024 | −28.16% |
| 2023 | +0.48% |
| 2022 | −23.61% |
| 2021 | −19.89% |
| 2020 | +9.75% |
| 2019 | +46.26% |
| 2018 | +4.45% |
| 2017 | +55.41% |
| 2016 (partial year) | −9.73% |
As of September 4, 2026.
TFX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $1.99B | −$905.64M | −45.4% |
| 2024 | $1.70B | $69.68M | 4.1% |
| 2023 | $1.71B | $356.33M | 20.8% |
| 2022 | $2.79B | $363.14M | 13.0% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $1.99B | $1.12B | $255.80M | −$905.64M | −45.4% |
| 2024 | $1.70B | $1.04B | $253.85M | $69.68M | 4.1% |
| 2023 | $1.71B | $1.04B | $303.75M | $356.33M | 20.8% |
| 2022 | $2.79B | $1.53B | $513.52M | $363.14M | 13.0% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
TFX Dividend History
Dividends per share, 2025 · 4 payments
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026* | $1.02 | 3 | — |
| 2025 | $1.36 | 4 | +0.0% |
| 2024 | $1.36 | 4 | +0.0% |
| 2023 | $1.36 | 4 | +0.0% |
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2026 (partial year) | $1.02 | 3 | — |
| 2025 | $1.36 | 4 | +0.0% |
| 2024 | $1.36 | 4 | +0.0% |
| 2023 | $1.36 | 4 | +0.0% |
| 2022 | $1.36 | 4 | +0.0% |
| 2021 | $1.36 | 4 | +0.0% |
| 2020 | $1.36 | 4 | +0.0% |
| 2019 | $1.36 | 4 | +0.0% |
| 2018 | $1.36 | 4 | +0.0% |
| 2017 | $1.36 | 4 | +300.0% |
| 2016 | $0.34 | 1 | — |
Most recent payment: $0.34 per share, ex-dividend August 14, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.
TFX Valuation vs Medical Instruments & Supplies Median
Median of 55 stocks| Metric | TFX | Medical Instruments & Supplies median | vs median |
|---|---|---|---|
| P/S ratio | 2.60 | 3.17 | 18% below |
| Profit margin | −45.76% | 0.85% | 46.6 pts below |
Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Needham Maintains Buy on Teleflex, Raises Price Target to $170
BenzingaTeleflex: Strong Company Undergoing Messy Transition, Hold
SeekingAlphaTeleflex: Portfolio Surgery Creates A Better Medtech Compounder
SeekingAlphaUBS Maintains Neutral on Teleflex, Raises Price Target to $158
BenzingaTruist Securities Maintains Hold on Teleflex, Raises Price Target to $150
BenzingaPiper Sandler Reiterates Overweight on Teleflex, Raises Price Target to $169
Benzinga
All 14 articles ↓Show fewer ↑
Teleflex Incorporated (TFX) Q2 2026 Earnings Call Transcript
SeekingAlphaTeleflex Incorporated 2026 Q2 - Results - Earnings Call Presentation
SeekingAlphaTeleflex Lowers FY2026 GAAP EPS Guidance from $2.90-$3.20 to $2.54-$2.84 vs $2.96 Est
BenzingaTeleflex Raises FY2026 Adj EPS Guidance from $6.25-$6.55 to $6.90-$7.20 vs $6.68 Est; Lowers FY2026 Sales Guidance from $2.280B-$2.300B to $2.260B-$2.280B vs $2.287B Est
BenzingaTeleflex Q2 Adj. EPS $1.76 Beats $1.28 Estimate, Sales $570.332M Beat $559.596M Estimate
BenzingaNeedham Maintains Buy on Teleflex, Raises Price Target to $159
BenzingaUBS Initiates Coverage of Teleflex (TFX) with Neutral Recommendation
FintelUBS Initiates Coverage On Teleflex with Neutral Rating, Announces Price Target of $145
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Medical Instruments & Supplies Stocks
Intuitive Surgical, Inc.
$131.38B
BDXBecton, Dickinson and Company
$50.32B
MDLNMedline Inc.
$49.23B
ALCAlcon Inc.
$34.08B
RMDResMed Inc.
$32.94B
WSTWest Pharmaceutical Services, Inc.
$23.93B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B











